RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Impact in
Classified as
- Journal
- Molecular Pharmaceutics
In The Last Decade
doi.org/10.1021/mp3002733 →Countries where authors are citing RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
This map shows the geographic impact of RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis more than expected).
Fields of papers citing RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
This network shows the impact of RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis.
About RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
This paper, published in 2012, received 807 indexed citations . Written by Fabienne Danhier, Aude Le Breton and Véronique Préat covering the research area of Immunology and Allergy, Immunology and Molecular Biology. It is primarily cited by scholars working on Molecular Biology (414 citations), Biomedical Engineering (302 citations), Biomaterials (289 citations), Immunology and Allergy (157 citations) and Oncology (122 citations). Published in Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1021/mp3002733.